|
|
CARDIOVASCULAR AND HEART HEALTHNorthwestern Medicine Bluhm Cardiovascular Institute has an enduring commitment to improving the heart health of our patients through expert care, advanced education and scientific breakthroughs. By placing an emphasis on listening to our patients’ needs, Bluhm Cardiovascular Institute has become a destination for those who need highly specialized cardiovascular care — from initial diagnoses to second opinions.
The Northwestern Memorial Hospital Cardiology, Heart and Vascular Surgery Program was ranked in the top 10 in the nation and has been the highest-ranked in Illinois for 17 straight years, per U.S. News & World Report, 2024 – 2025. Northwestern Medicine Bluhm Cardiovascular Institute has an enduring commitment to improving the heart and vascular health of our patients through expert care, advanced education and scientific breakthroughs from initial diagnoses to second opinions. Meet our executive leadership team.
|
Saved His Lungs to Save His Heart![]() How cardiac surgery, interventional cardiology and pulmonology came together to clear the clots deep in Mike's lungs. Read Mike’s story. |
ALT-FLOW II |
REACT-AF |
The purpose of this study is to assess the safety and effectiveness of the Edwards APTURE transcatheter shunt system for treatment of patients with heart failure due to left heart disease (HF-LHD) with mildly reduced or preserved ejection fraction (LVEF >40%) who remain symptomatic despite guideline-directed medical therapy (GDMT). Participants meeting eligibility criteria will be randomized in a 1:1 ratio to receive either the APTURE implant or a sham procedure (no further intervention). Participants randomized to the sham control group may be reassessed for treatment with the APTURE device. Participation requires follow-up visits with the study physician 30 days, 3 month, 6 months and annually through 5 years.
|
The purpose of this multi-center, randomized study is to assess whether it is safe and effective to stop oral anticoagulation medications (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF). Participants are randomized to one of two groups: Standard of Care (SOC) Group or Intervention Group. Participants in the SOC group will remain on their previously prescribed oral anticoagulant. Those randomized to the intervention group will take the oral anticoagulant for 30 days only if a prolonged episode of AF is detected on an AF-sensing Apple smartwatch. Participation will last up to 60 months and requires one visit to the same site at time of enrollment, all other follow-up will be conducted virtually.
|
Join Patrick M. McCarthy, MD, Douglas R. Johnston, MD, Kevin E. Hodges, MD, and Duc Thinh Pham, MD, as they reflect on driving innovation and excellence at Northwestern Medicine Bluhm Cardiovascular Institute over the last 20 years.
|
Featuring: Douglas R. Johnston, MD
|
December 2024 |
December 2024 Featuring: Douglas R. Johnston, MD
|
Featuring: Douglas R. Johnston, MD
|
Featuring: Douglas R. Johnston, MD
|
|
Heart Failure and Heart Transplantation Downtown Chicago Northern Suburbs Western Suburbs Greater DeKalb County Northwest Suburbs Southern Suburbs |
|
About Us Terms of Use Privacy Policy How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University |